IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum resistant epithelial ovarian cancer (EOC) patients (pts) Meeting Abstract
| Authors: | Moore, K. N.; Martin, L. P.; Matulonis, U. A.; Konner, J. A.; Seward, S. M.; Bauer, T. M.; O'Malley, D. M.; Perez, R. P.; Jeong, W. D.; Zhou, Y. H.; Kirby, M. W.; Mohanavelu, S.; Ruiz-Soto, R.; Birrer, M. J. |
| Abstract Title: | IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum resistant epithelial ovarian cancer (EOC) patients (pts) |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 305s |
| Language: | English |
| ACCESSION: | WOS:000404711501238 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.5567 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 5567 -- Source: Wos |
